Researchers have started using powerful computer simulations to design clinical trials, potentially reducing the failure rate and getting drugs to market faster. The simulators show whether a drug will yield statistically significant results using a certain set of test parameters. A recently approved simulator for Alzheimer's disease treatments incorporates data from previous trials, published papers and an NIH neuroimaging study.

Related Summaries